International Study for Treatment of High Risk Childhood Relapsed ALL 2010

The main goal of this study is to improve the outcome of children and adolescents with acute lymphoblastic leukemia with high risk first relapse by optimization of treatment strategies within a large international trial and the integration of new agents.

Trial Details

NCT ID
NCT03590171
Phase
PHASE2
Sponsor
Charite University, Berlin, Germany
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Bortezomib
Locations (sample)
  • Clayton, Victoria, Australia|-37.91667,145.11667
  • Vienna, Austria|48.20849,16.37208
  • Brussels, Belgium|50.85045,4.34878
  • Prague, Czechia|50.08804,14.42076
  • Copenhagen, Denmark|55.67594,12.56553

Key Eligibility Criteria

  • Morphologically confirmed diagnosis of 1st relapsed precursor B-cell or T-cell ALL
  • Children less than 18 years of age at date of inclusion into the study
  • Meeting HR criteria any BM relapse, early/very early isolated BM relapse, very early isolated/combined extramedullary relapse)
  • Patient enrolled in a participating centre

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →